DEF: Xeris Biopharma Holdings Sets Date for 2025 Annual Stockholders Meeting, Outlines Key Proposals

Xeris Biopharma Holdings will hold its 2025 Annual Meeting of Stockholders virtually on June 4, 2025, to elect directors, ratify the appointment of Ernst & Young LLP, and approve executive compensation.

Summary

• Xeris Biopharma Holdings will hold its 2025 Annual Meeting of Stockholders virtually on June 4, 2025, at 8:00 a.m. Central Time.
• Stockholders of record as of April 14, 2025, are entitled to vote.
• The meeting will address the election of three Class I directors, ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, and an advisory vote on executive compensation.
• Advance registration is required by June 3, 2025, at 5:00 p.m. Eastern Time via www.proxydocs.com/XERS.
• The board of directors recommends voting for the election of BJ Bormann, James Brady, and Garheng Kong as Class I directors.
• The board of directors recommends voting for the ratification of Ernst & Young LLP as the independent registered public accounting firm.
• The board of directors recommends voting for the approval of the compensation of the named executive officers.
• In 2024, Xeris Biopharma Holdings generated approximately $203.1 million in total revenue, exceeding initial guidance of $170-$200 million.
• The company ended 2024 with a cash balance of $71.6 million.
• The company's compensation committee approved a 110% corporate performance achievement level for all employees and NEOs for 2024.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong financial results and strategic initiatives. The company exceeded revenue expectations and maintained a strong cash position. The seamless CEO transition and focus on long-term value creation contribute to a favorable sentiment.

Positives

• The company achieved approximately $203.1 million in total revenue in 2024, exceeding initial guidance of $170-$200 million.
• The company ended 2024 with a cash balance of $71.6 million.
• The company's compensation committee approved a 110% corporate performance achievement level for all employees and NEOs for 2024.

Risks

• The document includes forward-looking statements that are subject to risks and uncertainties, as detailed in the company's 2024 Annual Report on Form 10-K.
• Actual results could differ materially from management's current expectations.

Future Outlook

The company is focused on the growth of innovative products, new product development, and technology partnerships to create long-term stockholder value.

Management Comments

• The Company has outperformed on our key financial targets, increased total product revenue by 28% and total revenue by approximately 24%.
• The Company managed total operating expenses (excluding cost of goods sold, amortization of intangible assets, and one-time costs associated with the CEO succession plan and related corporate restructuring) to 9% growth versus prior year while increasing total revenue by 24% versus prior year, ending with a strong cash position and the achievement of a cash flow positive quarter in the fourth quarter for the second time in the Company's history.

Industry Context

The document reflects standard corporate governance practices for publicly traded companies, including proxy statements, annual meetings, and executive compensation disclosures. The company operates in the competitive biotechnology industry, where attracting and retaining key executives is crucial.

Comparison to Industry Standards

• The document mentions benchmarking executive compensation against peer companies in the life sciences industry, including ADMA Biologics, Deciphera Pharmaceutical, and Rhythm Pharmaceuticals.
• The peer group was developed from commercial biopharma companies with market capitalizations of up to $1.5 billion, revenue between $100.0 and $600.0 million, and employee headcount up to 1,000 employees.
• The company's compensation practices are aligned with industry standards, including the use of independent compensation consultants and clawback policies.

Management Changes

Stakeholder Impact

• Shareholders: The proposals directly impact shareholders' voting rights and influence on corporate governance.
• Employees: Executive compensation decisions and benefit programs affect employee morale and retention.
• Customers: The company's strategic focus on product development and innovation aims to improve customer offerings.
• Suppliers: The company's financial performance and growth prospects can impact supplier relationships.
• Creditors: The company's financial stability and cash position are relevant to creditors.

Next Steps

• Stockholders to vote on the proposals outlined in the proxy statement.
• Company to hold the 2025 Annual Meeting of Stockholders on June 4, 2025.
• Company to continue executing its strategic plan focused on growth, innovation, and enterprise development.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Directors, Executive Compensation, Ernst & Young, Stockholders, Corporate Governance, Xeris Biopharma